Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03029351 · ClinicalTrials.gov registry record · Phase 4
GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes
A Phase 4 study, sponsored by University at Buffalo.
- Terminated
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT03029351 is a Phase 4 study that was terminated before completion, run by University at Buffalo. The registered enrollment target is 15 participants.
The verdict
NCT03029351, a Phase 4 study, was terminated before completion, sponsored by University at Buffalo.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a prospective study to evaluate effect of Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.
Interventions
- DRUG Placebo
- DRUG Exenatide Extended Release for Inj Susp 2 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-01-10 |
| Est. Completion | 2019-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03029351
The ClinicalTrials.gov registry entry for NCT03029351 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03029351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03029351 about?
NCT03029351 is a clinical study titled "GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes". This is a prospective study to evaluate effect of Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.
What is the current status of trial NCT03029351?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2017-01-10. Estimated completion is 2019-07.
What interventions are being tested in trial NCT03029351?
The interventions under investigation include: Placebo (DRUG), Exenatide Extended Release for Inj Susp 2 MG (DRUG).
Who is sponsoring clinical trial NCT03029351?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.